Cellectis (CLLS) Competitors $2.99 +0.10 (+3.46%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.00 +0.00 (+0.17%) As of 09/15/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. OPT, ARVN, OLMA, KOD, ATYR, AQST, ESPR, IVA, RAPP, and CYRXShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Opthea (OPT), Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Opthea Arvinas Olema Pharmaceuticals Kodiak Sciences aTyr Pharma Aquestive Therapeutics Esperion Therapeutics Inventiva Rapport Therapeutics CryoPort Opthea (NASDAQ:OPT) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Which has more volatility and risk, OPT or CLLS? Opthea has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500. Do institutionals and insiders believe in OPT or CLLS? 56.0% of Opthea shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, OPT or CLLS? Cellectis has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$30K19,437.00-$162.79MN/AN/ACellectis$49.22M3.38-$36.76M-$0.82-3.65 Do analysts prefer OPT or CLLS? Opthea presently has a consensus price target of $1.33, indicating a potential downside of 60.90%. Cellectis has a consensus price target of $4.00, indicating a potential upside of 33.78%. Given Cellectis' stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to OPT or CLLS? In the previous week, Cellectis had 1 more articles in the media than Opthea. MarketBeat recorded 2 mentions for Cellectis and 1 mentions for Opthea. Opthea's average media sentiment score of 1.89 beat Cellectis' score of 1.61 indicating that Opthea is being referred to more favorably in the media. Company Overall Sentiment Opthea Very Positive Cellectis Very Positive Is OPT or CLLS more profitable? Opthea has a net margin of 0.00% compared to Cellectis' net margin of -100.69%. Opthea's return on equity of 0.00% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Cellectis -100.69%-68.05%-21.53% SummaryCellectis beats Opthea on 9 of the 15 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$160.64M$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-3.6521.2475.1126.39Price / Sales3.38431.67511.76177.24Price / CashN/A44.4425.8129.91Price / Book1.279.6413.456.28Net Income-$36.76M-$53.20M$3.29B$270.38M7 Day Performance4.91%0.07%0.08%1.89%1 Month Performance4.91%4.27%4.59%6.01%1 Year Performance30.00%9.62%75.30%25.26% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis3.3764 of 5 stars$2.99+3.5%$4.00+33.8%+32.9%$160.64M$49.22M-3.65290Positive NewsShort Interest ↓Gap UpOPTOpthea0.4738 of 5 stars$3.41+7.2%$1.33-60.9%+8.2%$583.10M$30K0.008Gap UpHigh Trading VolumeARVNArvinas2.9935 of 5 stars$7.94+1.4%$19.76+148.9%-69.1%$574.86M$263.40M-7.86420Positive NewsOLMAOlema Pharmaceuticals2.8628 of 5 stars$7.58-8.8%$24.00+216.6%-37.0%$570.35MN/A-3.8370Gap UpKODKodiak Sciences3.9466 of 5 stars$9.79-6.9%$11.75+20.0%+245.0%$555.68MN/A0.0090Positive NewsGap UpATYRaTyr Pharma2.7861 of 5 stars$5.46-2.7%$23.25+325.8%-46.8%$549.71M$230K0.0053Trending NewsAnalyst ForecastGap DownAQSTAquestive Therapeutics2.0324 of 5 stars$5.01-7.6%$10.29+105.3%+6.2%$540.50M$57.56M-7.16160ESPREsperion Therapeutics3.91 of 5 stars$2.51-6.3%$7.00+178.9%+45.5%$540.35M$332.31M-5.12200Positive NewsIVAInventiva2.9851 of 5 stars$5.37-3.6%$14.83+176.2%+137.1%$532.84M$9.95M0.00100Short Interest ↑RAPPRapport Therapeutics2.6827 of 5 stars$31.47+119.2%$31.00-1.5%+30.2%$524.11MN/A0.00N/AAnalyst UpgradeHigh Trading VolumeCYRXCryoPort3.9982 of 5 stars$10.04-3.0%$12.00+19.5%+5.0%$518.19M$228.38M7.551,186Positive News Related Companies and Tools Related Companies OPT Alternatives ARVN Alternatives OLMA Alternatives KOD Alternatives ATYR Alternatives AQST Alternatives ESPR Alternatives IVA Alternatives RAPP Alternatives CYRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
